Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
$10.85
-$0.59(-1.49%)
At close: 4:00 PM EST
$10.85
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $44.28
Previous CloseN/A
Volume146.24K
Average Volume (3M)3.91M
Market Cap
$1.44B
Enterprise Value$1.71B
Total Cash (Recent Filing)$260.22M
Total Debt (Recent Filing)$314.18M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 19, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding132,688,490
10 Day Avg. Volume3,112,079
30 Day Avg. Volume3,905,092
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.55K
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$15.09Price Target Upside39.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-6.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionBiohaven’s $175M offering also alleviates a near-term financing overhang and provides a cushion to reaching potential value-driving readouts.
Pipeline AdvancementBiohaven's prioritized pipeline now consists of the Kv7, degrader, and myostatin programs, with depression data expected and Phase III epilepsy data being significant milestones.
Strategic FocusBiohaven is focusing on strategic portfolio and cost optimization, aiming to reduce annual direct R&D expenses by about 60%.
Bears Say
Competitive PositioningBHVN is 2+ years behind competitor Xenon in primary indication for Kv7, diminishing its competitive edge.
Market RisksThe biggest risk in the MDD trial is the creeping placebo effects that seem to be impacting large MDD and schizophrenia trials.
Regulatory ChallengesBiohaven announced that it received a CRL from the FDA for its NDA for Vyglxia (troriluzole) in SCA.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $44.28 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.44B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 19, 2026 which is in 86 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Nov 10, 2025. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.901 by $0.261.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -1.2.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 132,688,490 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.901. Following the earnings report the stock price went down -5.69%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.09 (39.08% Upside)
$15.09 (39.08% Upside)
Blogger Sentiment
Bearish
BHVN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.29%
12-Months-Change
Fundamentals
Return on Equity
-522.08%
Trailing 12-Months
Asset Growth
-19.86%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. (BHVN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for neurological and neuropsychiatric diseases. The company operates in the healthcare sector and specializes in addressing unmet medical needs within the central nervous system (CNS) disorders. Biohaven's core products include FDA-approved treatments for migraine and other CNS conditions, leveraging its proprietary platforms and extensive research capabilities.
BHVN Stock 12 Month Forecast
Average Price Target
$15.09
▲(39.08% Upside)
Technical Analysis
Ownership Overview
12.52% Insiders
11.58% Mutual Funds
20.62% Other Institutional Investors
46.46% Public Companies and
Individual Investors